KLP Kapitalforvaltning’s MoonLake Immunotherapeutics MLTX Stock Holding History

KLP Kapitalforvaltning’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$253K	Buy	13,000 +6,200	+91%	+$112K	﹤0.01%	1808
2026 Q1	$127K	Hold	6,800	–	–	﹤0.01%	1982
2025 Q4	$89.6K	Buy	6,800 +2,300	+51%	+$27.1K	﹤0.01%	2096
2025 Q3	$32.3K	Hold	4,500	–	–	﹤0.01%	2163
2025 Q2	$212K	Hold	4,500	–	–	﹤0.01%	1763
2025 Q1	$176K	Hold	4,500	–	–	﹤0.01%	1807
2024 Q4	$244K	Buy	+4,500	New	+$230K	﹤0.01%	1740

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

KLP Kapitalforvaltning's MLTX Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its MoonLake Immunotherapeutics (MLTX) stake by 91% in Q2 2026, buying an estimated $112K and bringing the position to 13,000 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #1808.

KLP Kapitalforvaltning first reported a position in MLTX in Q4 2024 and has held it in 7 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

KLP Kapitalforvaltning held 13,000 shares of MoonLake Immunotherapeutics worth $253K as of Q2 2026.
KLP Kapitalforvaltning bought 6,200 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $112K.
MoonLake Immunotherapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1808 holding.
KLP Kapitalforvaltning first reported a position in MoonLake Immunotherapeutics in Q4 2024 and has held it in 7 quarters since.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.